These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 30522957)
1. Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors. Kim YY; Choi J; Choi K; Park C; Kim YH; Suh KH; Ham YJ; Jang SY; Lee KH; Hwang KW Bioorg Med Chem Lett; 2019 Jan; 29(2):271-275. PubMed ID: 30522957 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity. Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427 [TBL] [Abstract][Full Text] [Related]
3. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB; Mehany ABM; Abdellatif KRA Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition. Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132 [TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058 [TBL] [Abstract][Full Text] [Related]
6. Synthetic strategy for increasing solubility of potential FLT3 inhibitor thieno[2,3-d]pyrimidine derivatives through structural modifications at the C Oh C; Kim H; Kang JS; Yun J; Sim J; Kim HM; Han G Bioorg Med Chem Lett; 2017 Feb; 27(3):496-500. PubMed ID: 28043794 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors. Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines. Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475 [TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies. El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents. Ghith A; Youssef KM; Ismail NSM; Abouzid KAM Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors. Sun W; Hu S; Fang S; Yan H Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives. Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents. Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors. Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors. Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706 [TBL] [Abstract][Full Text] [Related]
16. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
17. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719 [TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors. Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007 [TBL] [Abstract][Full Text] [Related]
20. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]